Overactive Bladder (OAB): What We Thought We Knew and What We Know Today  William D Steers  European Urology Supplements  Volume 1, Issue 4, Pages 3-10 (July 2002) DOI: 10.1016/S1569-9056(02)00042-8

Fig. 1 Prevalence of medical consultation and current medication in 1916 men and women aged 40–74 years with chronic bothersome OAB symptoms. Adapted with permission from [3]. European Urology Supplements 2002 1, 3-10DOI: (10.1016/S1569-9056(02)00042-8)

Fig. 2 Role of the urothelium in OAB. Adapted with permission from [24]. VR: vanilloid; P: purinergic; NGF: nerve growth factor; trk-A: tyrosine kinase A; NO: nitric oxide; NK: neurokinin. European Urology Supplements 2002 1, 3-10DOI: (10.1016/S1569-9056(02)00042-8)

Fig. 3 Role of neuronal growth factor (NGF) in neural activity. Adapted with permission from [24]. European Urology Supplements 2002 1, 3-10DOI: (10.1016/S1569-9056(02)00042-8)

Fig. 4 Percent of patients with depression in subgroups of patients with incontinence. Depression diagnosed by history and/or Beck Depression Inventory (BDI) scoring. Adapted with permission from [27]. European Urology Supplements 2002 1, 3-10DOI: (10.1016/S1569-9056(02)00042-8)